US HB2011 | 2019-2020 | 116th Congress

Status

Spectrum: Slight Partisan Bill (Republican 4-2)
Status: Introduced on April 1 2019 - 25% progression, died in committee
Action: 2019-04-02 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

To amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biologics license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Protecting Access to Biosimilars Act of 2019

Sponsors


History

DateChamberAction
2019-04-02HouseReferred to the Subcommittee on Health.
2019-04-01HouseReferred to the House Committee on Energy and Commerce.
2019-04-01HouseIntroduced in House

Same As/Similar To

SB1140 (Related) 2019-04-11 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
SB1895 (Related) 2019-07-08 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 133.

Subjects


US Congress State Sources


Bill Comments

feedback